

We are Proud to Have Partnered on 55 New INN Name Approvals!

Company	Name	Company	Name
1. AbbVie	foscarbidopa	29. Immune Design	baloramotide
2. AbbVie	foslevodopa	30. Immune Design	cadalimogene ixalenticvec
3. AbbVie	serclutamab	31. Immune Design	lapretolimod
4. AbbVie	serclutamab talirine	32. Janssen	teclistamab
5. AbbVie	tamrintamab	33. Khondrion	sonlicromanol
6. AbbVie	tamrintamab pamozirine	34. Loxo	selitrectinib
7. AbbVie	tilavonemab	35. Loxo	selpercatinib
8. Acticor	glenzocimab	36. Microbion	pravibismane
9. Agenus	zalifrelimab	37. MyoKardia	danicamtiv
10. Allergan	vimirogant	38. Neurocrine	crinecerfont
11. Amgen	rozibafusp alfa	39. NGM	aldafermin
12. Apeiron	lorukafusp alfa	40. Oncomed	efaprinermin alfa
13. Avelas	pegloprastide	41. Rafeal	devimistat
14. Basilea	avanbulin	42. REMD	volagidemab
15. BioCancell	inodiftagene vixteplasmid	43. Sage	zuranolone
16. BioLine	motixafortide	44. Sangamo	adlinacogene civaparovec
17. BioSight	aspacytarabine	45. Sangamo	devafidugene
18. Blueprint	fisogatinib	46. Sangamo	inlezifigene civaparovec
19. Celgene	cendakimab	47. Sangamo	ranuzifigene civaparovec
20. Daewoong	fexuprazan	48. Sangamo	tefidsogene civaparovec
21. Effector	zotatifin	49. SCM LifeScience	mocemestrocel
22. Enterome	sibofimloc	50. Takeda	simurosertib
23. Forty Seven	magrolimab	51. Ultragenyx	triheptanoin
24. Gilead	elipovimab	52. UniQure	etranacogene dezaparovec
25. Gilead	selgantolimod	53. Valerion	clervonafusp alfa
26. GNT Pharma	crisdesalazine	54. Vidac	tuvatexib
27. Hanall	tafanercept	55. Zafgen	aclimostat
28. IMedImmune	efgivanermin alfa		

Sophia V. Fuerst, M.S., M.B.A. DSI President of Nonproprietary Names Division, Drug Safety Institute



Ms. Fuerst is President of Drug Safety Institute's Nonproprietary (USAN/INN) Names Division. Ms. Fuerst was formerly Director of the USAN Program at the American Medical Association (AMA) and served in various positions during her 18-year tenure with the Program.

She was involved in negotiations between the USAN Council, pharmaceutical manufacturers and foreign nomenclature agencies. From 1986 to 2005 Ms. Fuerst was responsible for reviewing submissions, classifying compounds, creation of new stems when appropriate and approval and adoption of new USAN. Ms. Fuerst also sat on the World Health Organization (WHO/INN) Committee and served as AMA's senior staff scientist in the area of Drug Nomenclature.

Ms. Fuerst holds a B.S. in Biology/Chemistry (pre-med) from St. Joseph's College, an M.S. in Medicinal Chemistry from the University of Chicago and an M.B.A. from Governor's State University in Illinois.